桂枝汤抗高血压潜在机制:网络药理学与Dahl盐敏感大鼠模型研究
本研究整合网络药理学与Dahl盐敏感大鼠模型,探讨桂枝汤抗高血压的潜在机制。结果获得112个活性成分、222个桂枝汤靶点及341个高血压相关靶点,56个重叠靶点主要富集于TNF、TLR、NF-κB等炎症通路;实验证实桂枝汤改善血压、减少心脏纤维化面积并抑制IL-6、CCL2、IL-1β、MMP-2和MMP-9表达。
要点
- 桂枝汤可能通过调控心脏炎症与纤维化发挥抗高血压作用。
- 网络药理学提示TNF、TLR、NF-κB等炎症通路为关键通路。
- Dahl盐敏感大鼠实验显示桂枝汤改善血压并减少心脏纤维化面积。
核心结论
- 桂枝汤抗高血压的潜在机制与治疗效应可能归因于对心脏炎症和纤维化的调控。
研究设计与样本
- 研究采用网络药理学分析结合Dahl盐敏感大鼠模型实验验证。
- 从TCMSP数据库收集桂枝汤活性成分及对应靶点,从CTD、GeneCards、OMIM和Drugbank数据库识别高血压相关靶点。
- 构建多重网络识别关键化合物、枢纽靶点及主要生物学过程和通路,并用Surflex-Dock软件验证关键靶点与活性化合物的结合亲和力。
- 使用Dahl盐敏感大鼠模型评估桂枝汤抗高血压的治疗效应。
主要发现
- 共获得112个活性成分、222个桂枝汤靶点和341个高血压相关靶点,鉴定出56个重叠靶点。
- 确定IL-6、CCL2、IL-1β、MMP-2和MMP-9五个枢纽靶点进行实验验证。
- 通路富集分析显示56个重叠靶点主要富集于TNF信号通路、TLR信号通路和NF-κB信号通路等炎症通路。
- 分子对接证实桂枝汤多数活性化合物可与关键靶点紧密结合。
- 实验研究表明给予桂枝汤改善大鼠血压、减少心脏纤维化面积并抑制IL-6、CCL2、IL-1β、MMP-2和MMP-9表达。
临床怎么用
- 对于高血压患者,尤其关注心脏炎症与纤维化调控时,可考虑桂枝汤的潜在应用价值。
- 临床决策时可参考桂枝汤多成分、多靶点调控炎症通路的网络药理学证据。
- 需结合实验验证的枢纽靶点IL-6、CCL2、IL-1β、MMP-2和MMP-9评估桂枝汤的效应机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Guizhi decoction (GZD), a classical Chinese herbal formula, has been widely used to treat hypertension, but its underlying mechanisms remain elusive. The present study aimed to explore the potential mechanisms and therapeutic effects of GZD on hypertension by integrating network pharmacology and experimental validation. METHODS: The active ingredients and corresponding targets were collected from the Traditional Chinese Medicine Systems Pharmacology database and Analysis Platform (TCMSP). The targets related to hypertension were identified from the CTD, GeneCards, OMIM and Drugbank databases. Multiple networks were constructed to identify the key compounds, hub targets, and main biological processes and pathways of GZD against hypertension. The Surflex-Dock software was used to validate the binding affinity between key targets and their corresponding active compounds. The Dahl salt-sensitive rat model was used to evaluate the therapeutic effects of GZD against hypertension. RESULTS: A total of 112 active ingredients, 222 targets of GZD and 341 hypertension-related targets were obtained. Furthermore, 56 overlapping targets were identified, five of which were determined as the hub targets for experimental verification, including interleukin 6 (IL-6), C-C motif chemokine 2 (CCL2), IL-1β, matrix metalloproteinase 2 (MMP-2), and MMP-9. Pathway enrichment analysis results indicated that 56 overlapping targets were mainly enriched in several inflammation pathways such as the tumor necrosis factor (TNF) signaling pathway, Toll-like receptor (TLR) signaling pathway and nuclear factor kappa-B (NF-κB) signaling pathway. Molecular docking confirmed that most active compounds of GZD could bind tightly to the key targets. Experimental studies revealed that the administration of GZD improved blood pressure, reduced the area of cardiac fibrosis, and inhibited the expression of IL-6, CCL2, IL-1β, MMP-2 and MMP-9 in rats. CONCLUSION: The potential mechanisms and therapeutic effects of GZD on hypertension may be attributed to the regulation of cardiac inflammation and fibrosis.
引用
- Chen J, Zhang Y, Wang Y, et al. Potential mechanisms of Guizhi decoction against hypertension based on network pharmacology and Dahl salt-sensitive rat model. Chin Med. 2021. PMID: 33906674. doi:10.1186/s13020-021-00446-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。